FTV

AI Memo

Fortive

As of 2026-05-03/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-03 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Next update must prove growth quality beyond selling days and absorb tariff/financing pressure [#10-Q-2026-04-30] • 2026-07-31

Expected move: +2%

Biggest risk

The beat was not clean enough to force estimate or multiple expansion because the quarter benefited from extra selling days, full-year guidance was only reaffirmed rather than raised, and management still cited tariff effects and persistent hospital capital-spending pressure. No clear post-print target-hike wave or rating-change signal was found in the checked sources as of 2026-05-03.

Invalidation

Break below $54 or thesis failure.

What would change my mind?

The checked company sources support a constructive operational read: Q1 revenue rose 7.7%, adjusted EPS rose 25.4%, free cash flow was $194 million, and management said full-year results are trending toward the upper half of the reaffirmed range. The packet's median analyst target of $62.19 is modestly above the $59.03 anchor.

Research note

Recommendation

—

Confidence

medium

As of

2026-05-03

Base target

$62

p=50%

Bull target

$66

p=25%

Bear target

$54

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q1 beat is being repriced against unchanged full-year guidance [#8-K-2026-04-30]
Buybacks, segment margin improvement, and backlog-like revenue visibility can support a gradual recovery [#10-Q-2026-04-30]
The checked company sources support a constructive operational read: Q1 revenue rose 7.7%, adjusted EPS rose 25.4%, free cash flow was $194 million, and management said full-year results are trending toward the upper half of the reaffirmed range.

BearKey bullets

Commercial paper increased to $1.241 billion at April 3, 2026, raising sensitivity to financing costs even though liquidity remains adequate.
Hospital spending pressure still persists in low-temperature sterilization capital, limiting the quality of healthcare-side acceleration.
No confirmed post-print analyst target-hike or estimate-revision wave was identified in checked sources by May 3, 2026, limiting external validation of the bullish read.

WatchKey bullets

Next update must prove growth quality beyond selling days and absorb tariff/financing pressure [#10-Q-2026-04-30]

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $62 (p=50%)

Bull/Bear spread: +9% / -11%

Vs latest close: Bull +9% · Base +2% · Bear -11%

Scenario probabilities

Bull Target: $66 (p=25%)Base Target: $62 (p=50%)Bear Target: $54 (p=25%)

Commentary

Primary-source tone is positive, but the T+3 read is still mixed. Fortive's April 30, 2026 release showed a solid beat-and-reaffirm quarter, yet Reuters-syndicated coverage emphasized the benefit from extra selling days and unchanged full-year guidance. Using checked price points, the stock moved from an April 29, 2026 close of $61.75 to the May 1, 2026 anchor close of $59.03, a drop of about 4.4% after the print. Because no clear delayed analyst revision wave was confirmed in checked sources by May 3, 2026, this remains more of a cautious monitoring setup than a strong post-earnings momentum call.

As of 2026-05-03 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q1 beat is being repriced against unchanged full-year guidance [#8-K-2026-04-30]
Buybacks, segment margin improvement, and backlog-like revenue visibility can support a gradual recovery [#10-Q-2026-04-30]

Scenarios

Bull Target (Scenario probability)

$66 / p=25% prob

Base Target (Scenario probability)

$62 / p=50% prob

Bear Target (Scenario probability)

$54 / p=25% prob

Price $61 as of 2026-07-23

Nearest Scenario: Base (∆ 2%)

Targets vs latest close: Bull +9% · Base +2% · Bear -11%

Sentiment & Exposure

News Sentiment (30d)

0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-07-31
Next update must prove growth quality beyond selling days and absorb tariff/financing pressure [#10-Q-2026-04-30]
Management flagged expected impact from tariffs and trade policy in the 10-Q risk discussion, while commercial paper rose to $1.241 billion at quarter-end and hospital spending pressures were said to persist in low-temperature sterilization. If the next quarter does not show clean organic follow-through without calendar help, the stock could remain range-bound or de-rate. [#10-Q-2026-04-30]
Prob 55.00% • Move -7.00% • Priced-in 42.00%

Short-term Catalysts

Next few weeks

Q1 beat is being repriced against unchanged full-year guidance [#8-K-2026-04-30]
2026-05-20
Fortive reported Q1 revenue of $1.069 billion, adjusted EPS of $0.70, core growth of 5.3%, and said FY2026 adjusted EPS remains $2.90-$3.00 while trending toward the upper half; the release also noted an approximately 150 bps selling-day benefit, which helps explain why a beat did not force a cleaner rerating. Reuters-syndicated coverage reviewed after the print cited $0.64 consensus adjusted EPS versus the reported $0.70. [#8-K-2026-04-30]
Prob 70% • Move 4% • Priced-in 60%

Long-term Catalysts

Months to a year

Buybacks, segment margin improvement, and backlog-like revenue visibility can support a gradual recovery [#10-Q-2026-04-30]
2026-07-31
The Q1 filing showed 8.9 million shares repurchased for about $500 million at an average price of $56.21, Advanced Healthcare Solutions adjusted EBITDA margin up to 25.7% from 23.6%, and remaining performance obligations of $839.9 million, with most expected to convert over the next two to four years. That mix supports a steady execution case even if the near-term rerating stays muted. [#10-Q-2026-04-30]
Prob 62% • Move 6% • Priced-in 48%

Risks

Commercial paper increased to $1.241 billion at April 3, 2026, raising sensitivity to financing costs even though liquidity remains adequate.
Hospital spending pressure still persists in low-temperature sterilization capital, limiting the quality of healthcare-side acceleration.
No confirmed post-print analyst target-hike or estimate-revision wave was identified in checked sources by May 3, 2026, limiting external validation of the bullish read.
Tariff, trade-policy, and supply-chain pressures remain explicit risk factors in the Q1 2026 10-Q.
The post-earnings setup is vulnerable if investors conclude Q1 benefited disproportionately from extra selling days rather than durable demand acceleration.

Peers

Symbol	Summary
AME	AMETEK is a closer instrumentation and engineered-technology comparator for Fortive than broad electrical peers; it is useful for benchmarking industrial measurement exposure, pricing discipline, and margin execution.
IEX	IDEX is a direct industrial technology peer with specialized fluidics, health and science, and engineered-product exposure; it is a better operating comp for Fortive's portfolio-quality and margin conversion than larger diversified automation names.
ROP	Roper Technologies is a higher-quality software and engineered-products benchmark for Fortive's recurring-revenue and portfolio-upgrade narrative, though Roper's stronger software mix means Fortive still needs cleaner organic growth to justify a similar multiple.
TRMB	Trimble is relevant for Fortive's software-enabled workflow and field-productivity businesses, but its end-market mix differs, so it should be used as a partial benchmark rather than a full operating match.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-05-03

AI Stock Memo: FTV - Fortive - RankAlpha